Notice of the 40th Annual General Meeting to be held on 30th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has called its 40th AGM on Tuesday, 30th September 2025 at 4:30 PM, to be held entirely through video conferencing. Shareholders will vote on adopting the audited standalone and consolidated financial statements for FY ended 31st March 2025, reappointing Shashank Sandu (DIN: 00678098) as a director retiring by rotation, and declaring a dividend of 8% (₹0.80 per share) on equity shares of ₹10 face value. Other items include ratifying the cost auditor's remuneration of ₹1,15,000, appointing M/s Swapnil J Dixit & Associates as secretarial auditor for a 5-year term (FY 2025-26 to FY 2029-30), approving material related party transactions with Sandu Brothers Private Limited up to ₹100 crore, and continuing Vijay Kajarekar as CFO past his turning 70 in June 2026. The register of members will be closed from 23rd to 30th September 2025, with the cut-off date for e-voting set as 23rd September 2025 and e-voting open from 27th to 29th September 2025. Dividend, if approved, will be paid on or before 25th October 2025.
Mostly routine AGM agenda, but shareholders should note the proposed ₹100 crore related party transaction ceiling with Sandu Brothers Private Limited, a related party, which warrants attention. The 8% dividend declaration is positive for income-focused shareholders, with payment expected by 25th October 2025 subject to shareholder approval.